SciClone Pharmaceuticals (Holdings) Limited Sustainability Profile
SciClone Pharmaceuticals (Holdings) Limited, headquartered in China, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies. Founded in 1995, the company has made significant strides in addressing unmet medical needs, particularly in oncology and infectious diseases. With a strong operational presence in Asia and expanding into global markets, SciClone is renowned for its flagship product, ZADAXIN, a thymosin alpha 1 therapy that enhances immune response. This unique offering positions the company as a leader in immunotherapy, catering to both patients and healthcare providers. SciClone's commitment to research and development, coupled with strategic partnerships, has solidified its market position, making it a key contributor to the advancement of biopharmaceutical solutions. The company continues to focus on delivering high-quality, effective treatments that improve patient outcomes worldwide.
DitchCarbon Score
How does SciClone Pharmaceuticals (Holdings) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SciClone Pharmaceuticals (Holdings) Limited's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SciClone Pharmaceuticals (Holdings) Limited's reported carbon emissions
In 2022, SciClone Pharmaceuticals (Holdings) Limited reported total carbon emissions of approximately 17,179,520 kg CO2e, comprising 5,031,790 kg CO2e from Scope 1 emissions and 12,147,730 kg CO2e from Scope 2 emissions. This data reflects the company's global operations and highlights its significant carbon footprint. In 2021, the company disclosed emissions of about 9,385,520 kg CO2e globally, with 117,100 kg CO2e from Scope 1 and 9,268,410 kg CO2e from Scope 2. In contrast, its emissions in China for the same year were reported at 111,180 kg CO2e, all from Scope 2. The 2020 emissions data for China indicated a total of 292,800 kg CO2e, again solely from Scope 2. Despite these figures, SciClone Pharmaceuticals has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company has not cascaded emissions data from any parent or related organizations, indicating that all reported figures are derived directly from its own operations. Overall, while SciClone Pharmaceuticals has made strides in emissions reporting, it currently lacks defined climate commitments or reduction strategies to mitigate its carbon emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 117,100 | 0,000,000 |
| Scope 2 | 9,268,410 | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is SciClone Pharmaceuticals (Holdings) Limited's Industry?
How Carbon Intensive is SciClone Pharmaceuticals (Holdings) Limited's Location?
SciClone Pharmaceuticals (Holdings) Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SciClone Pharmaceuticals (Holdings) Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
